Rifampin, a useful drug for nonmycobacterial infections.
Rifampin has clinical efficacy against a wide variety of organisms, including Staphylococcus aureus, Legionella pneumophila, group A Streptococcus, Brucella sp, Haemophilus influenzae, and Neisseria meningitidis, as well as in vitro activity against penicillin-resistant Streptococcus pneumoniae, Neisseria gonorrhoeae, Chlamydia trachomatis, Haemophilus ducreyi, and many gram-negative rods. Rifampin is a useful drug for several types of bacterial infections because of its broad spectrum of activity, excellent tissue penetration, and low side effect profile. In combination with other antibiotics, it may be effective when conventional therapies are not.
Vesely
J J
JJ
Department of Medicine, University of Hawaii, John Burns School of Medicine, and Straub Clinic and Hospital, Honolulu, USA.
Pien
F D
FD
Pien
B C
BC
D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D009161:Mycobacterium / Q000187:drug effects; D009164:Mycobacterium Infections / Q000188:drug therapy; D012293:Rifampin / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy
D000904:Antibiotics, Antitubercular; D012293:Rifampin